Can you name the cancer keytruda was primarily designed to treat?

What Cancer did Keytruda Originally Target?

Keytruda, also known as pembrolizumab, is a monoclonal antibody that blocks the PD-1 receptor, a protein on the surface of T-cells, to prevent cancer cells from evading the immune system. The medication was primarily designed to treat melanoma, specifically unresectable or metastatic melanoma. This indication was first approved by the US FDA in September 2014 [1].

Melanoma Treatment Success

Keytruda's approval for melanoma treatment marked a significant shift in cancer therapy, representing the first checkpoint inhibitor to receive FDA approval for a type of cancer. This development led to a substantial improvement in overall survival for patients with advanced melanoma, showing that Keytruda can slow down cancer growth in about 30% of patients.

Further Indications

In the years since its approval, Keytruda has been expanded to include treatment for other types of cancer, including:

- Non-small cell lung cancer (NSCLC) [2]
- Head and neck squamous cell carcinoma
- Renal cell carcinoma
- Classical Hodgkin lymphoma
- Squamous cell carcinoma of the bladder

These developments have made Keytruda a cornerstone in the treatment of various cancers, underscoring its value in targeted therapy.

Sources:

[1] DrugPatentWatch.com - Keytruda (pembrolizumab) for Melanoma

[2] https://www.drugpatentwatch.com/drugs/melphalan-and-pembro/